Press Releases - 2020-06-03

Date	Title	Company
03-Jun-2020	AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis	AbbVie
03-Jun-2020	ASCO 2020: UK-first study shows feasibility of genetic screening for prostate cancer	The Institute of Cancer Research
03-Jun-2020	Sanofi to launch “Action 2020”, a worldwide employee stock purchase plan	Sanofi
03-Jun-2020	Medios AG resolves on capital increase against cash contributions of up to almost 10% of the share capital	Medios AG
03-Jun-2020	RXVIP Co-Founders Launch the CareONE Concierge Academy to Set a New Standard of Patient and Student Experiential Engagement to Help Address the COVID-19 Damage to the Pharmacy Educational System	Newswire
03-Jun-2020	RHÖN-KLINIKUM Aktiengesellschaft: CEO directs appeal in the virtual extraordinary general meeting to large shareholders and emphasises widespread dedication in tackling COVID-19 pandemic - Changes in Supervisory Board	RHÖN-KLINIKUM Aktiengesellschaft
03-Jun-2020	NMI® at 45.4%; May 2020 Non-Manufacturing ISM® Report On Business®	Institute for Supply Management
03-Jun-2020	Eleva's Drug Candidate to Be Examined for Use in COVID-19 Treatment	eleva GmbH
03-Jun-2020	New First-in-Class Phase 3 TREMFYA®▼ (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52	Janssen
03-Jun-2020	ERT Survey Indicates Swift Adoption of Virtual Clinical Trials Due to COVID-19	ERT
03-Jun-2020	Absorption Systems named one of top 10 CROs in 2020	Absorption Systems
03-Jun-2020	CPhI Worldwide 2020 Implements new ‘Informa AllSecure Standard’	CPhI Worldwide
03-Jun-2020	Sygnature expands capabilities with acquisition of Alderley Oncology	Sygnature Discovery
03-Jun-2020	Hoth Therapeutics Provides Shareholder Update on Therapeutics Pipeline	Hoth Therapeutics, Inc.
03-Jun-2020	AbbVie to Present at the Virtual Goldman Sachs 41st Annual Global Healthcare Conference	AbbVie
03-Jun-2020	New First-in-Class Phase 3 TREMFYA® (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52	The Janssen Pharmaceutical Companies of Johnson & Johnson
03-Jun-2020	Johnson & Johnson Receives Positive CHMP Opinion for Janssen’s Investigational Preventive Ebola Vaccine Regimen	Johnson & Johnson
03-Jun-2020	Lonza to Host New Webinar – “The Compendia are ready. Are you? A More Sustainable Future for Endotoxin Testing”	Lonza
03-Jun-2020	UCB and N-SIDE increase their strategic collaboration	N-SIDE
03-Jun-2020	Katana Pharmaceuticals Awarded up to $1.05 Million Innovative Challenge Grant from March of Dimes to Support the Development of a Novel Non-Opioid Treatment for Neonatal Abstinence Syndrome	Katana Pharmaceuticals Inc.